Questcor Pharmaceuticals Inc (QCOR): Citron ‘Must Read Report’

Questcor Pharmaceuticals Inc (QCOR): Citron ‘Must Read Report’
PeteLinforth / Pixabay

Citron Research with bearish report on Questcor Pharmaceuticals Inc (NASDAQ:QCOR)

In what might be our most socially relevant report to date Citron exposes explosive findings behind the true components of Questcor Pharmaceuticals Inc (NASDAQ:QCOR) flagship drug HP Acthar Gel.  This is a must read for all investors, as Citron has taken the extra steps necessary to uncover the “mystery” active ingredients in one of the most controversial drugs on the marketplace.  

Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has been a battleground stock for years.  Bulls have stood by the strong financial performance of the company, while bears have been clinging to the threat of multiple government investigations and lack of clinical data for this “magical” $30,000 per vial drug.

Citron Research is very aware of the grave nature of the above headline, and the impact of information disclosed in this story. We understand clearly that there are consequences for making statements that are false or based upon incorrect assumptions. We have been exposing fraud for 13 years and have never hidden behind a guise of anonymity. We have always invited our work to be subject to legal scrutiny. That being said, we ask all Questcor shareholders – long and short – to take a big breath, sit down, and read. Citron publishes what we

Bonhoeffer Fund July 2022 Performance Update